DAA in the Risk of Recurrence After Curative Treatment of HCC

NCT02959359 · clinicaltrials.gov ↗

PHASE4

Phase

WITHDRAWN

Status

OTHER_GOV

Sponsor class

Stopped The supplies of study drug were halted by Gilead Sciences Ltd.

Conditions

Hepatocellular Carcinoma

Interventions

DRUG: Ledipasvir 90mg/Sofosbuvir 400 mg
DRUG: Ribavirin

Sponsor

Taipei Veterans General Hospital, Taiwan

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]